Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
doi: 10.1038/aps.2016.21 Summary Keywords metformin, intestinal microbiota, gastrointestinal mucosal barrier, SCFAs, bile acid metabolism Citation Wang Y, Jia X and Cong B (2024) Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota
As of now, oral forms of GLP-1s should not be assumed safe during breastfeeding
Ozempic for CKD and heart disease The FLOW phase 3b clinical trial (NCT03819153) demonstrated that when Ozempic 1 mg injection was used in adults with type 2 diabetes and CKD, Ozempic demonstrated: 24% reduced the risk of kidney disease progression, kidney failure, and cardiovascular death at 3 years when compared to placebo
This case highlights the ongoing supply issues faced by GLP-1 medications like Zepbound, Mounjaro, and Novo Nordisks Wegovy, which have been in high demand
128 GLP-1RAs and GLP-1/GIP dual-receptor agonists have demonstrated the capacity to enhance insulin sensitivity and exert antioxidant and anti-inflammatory effects in the brain
